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Abstract: Recently, the potential use of cold atmospheric pressure plasma (CAP) in cancer treatment
has gained increasing interest. Especially the enhanced selective killing of tumor cells compared
to normal cells has prompted researchers to elucidate the molecular mechanisms for the efficacy of
CAP in cancer treatment. This review summarizes the current understanding of how CAP triggers
intracellular pathways that induce growth inhibition or cell death. We discuss what factors may
contribute to the potential selectivity of CAP towards cancer cells compared to their non-malignant
counterparts. Furthermore, the potential of CAP to trigger an immune response is briefly discussed.
Finally, this overview demonstrates how these concepts bear first fruits in clinical applications
applying CAP treatment in head and neck squamous cell cancer as well as actinic keratosis. Although
significant progress towards understanding the underlying mechanisms regarding the efficacy of CAP
in cancer treatment has been made, much still needs to be done with respect to different treatment
conditions and comparison of malignant and non-malignant cells of the same cell type and same
donor. Furthermore, clinical pilot studies and the assessment of systemic effects will be of tremendous
importance towards bringing this innovative technology into clinical practice.
Keywords: cold physical plasma; plasma medicine; reactive oxygen and nitrogen species
1. Introduction
For some 20 years, physical plasmas have been used in clinical applications. While thermal
(hot) plasmas that are, for example, commonly used in endoscopic tissue coagulation [1] destruction
of human tissues, nonthermal (cold) plasmas can be used in clinical applications without harming
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the treated tissue. Plasma is an ionized gas generated by adding energy in the form of heat or
electromagnetic fields to a neutral gas. Such an excited gas contains free charged particles, radicals,
UV-radiation, electric fields, and often high temperatures [2]. Plasma treatment generates reactive
oxygen and nitrogen species, including O, O3, OH, H2O2, HO2, NO, ONOOH amongst many others.
According to the current understanding, especially reactive oxygen and nitrogen species (RONS),
generated by CAP, induce oxidative damage in the cell, resulting in cell death [3–5]. The use of
nonthermal plasmas, especially cold atmospheric pressure plasmas (CAP) has been assessed for a
variety of different clinical applications including disinfection, wound healing, treatment of atopic
eczemas, itch, pain, skin barrier dysfunctions and scars [6]. More recently, the potential use of CAP in
cancer treatment has gained increasing attention [7]. In contrast to other applications such as wound
healing, the use of CAP in cancer treatment aims at killing the treated tumor cells using prolonged
treatment times. In order to understand and improve the efficacy of CAP in cancer treatment it is
essential to gain insights regarding the underlying mechanisms of action. Therefore, in this review, we
discuss the current understanding of how CAP induces cell death and what factors may contribute to
its selectivity towards cancer cells compared to their non-malignant counterparts. First, the immediate
effect of plasma components on the treated cells as well as differences between cells that may lead to an
enhances sensitivity of cancer cells are discussed followed by a discussion of downstream consequences
and signaling pathways that finally induce cell death. Furthermore, we discuss the potential of CAP
to trigger an immune response, and thus, its use in combinatorial therapies. Finally, our overview
demonstrates how these concepts bear first fruits in clinical applications applying CAP treatment in
head and neck squamous cell cancer as well as actinic keratosis.
2. Selectivity of CAP towards Malignant Cells
The potential selectivity of CAP towards cancer cells compared to their non-malignant counterparts
has enhanced the interest in CAP as an innovative cancer treatment. A review of literature comparing
cancer cells to homologous normal cells by Yan et al. revealed that 26 of 33 assessed cell lines showed a
strong selectivity, 5 of 33 a weak selectivity, and only 2 of 33 showed a negative selectivity [8]. However,
it is important to note, that in this context “homology” had been defined to indicate that cancer cells
and normal cells originate from the same tissue type. That means the cells which had been compared
in this study have not necessarily been of the same cell type and they didn’t necessarily originate from
the same individual. In many cases the cancer cells were cultured in different media compared to the
normal cells [9–15]. However, it is now a well-accepted expectation that a selectivity study should
compare malignant and normal cells derived from the same tissue. Furthermore, cells should also be
of the same cell type and cultured under comparable conditions. In fact, a recent study has shown,
that cell type, cancer type, and culture conditions strongly influence CAP treatment and hence need
to be considered when selectivity of CAP is determined [16]. A study comparing a human breast
cancer cell line (MCF7) with a normal breast epithelial cell line (MCF10A) showed a dramatically
reduced viability of the cancer cells comparted to the normal cells after CAP treatment [9]. However,
the two cell lines were not cultured in identical media. The importance of using the same culture
medium to test for selectivity was demonstrated elegantly in a study that also compared a human
breast cancer cell line (MDA-MB-231) with a normal breast epithelial cell line (MCF10A) [17]. In this
study, migration and circularity of the cells were used as proxies for cell viability and functionality.
Using a DMEM-based medium, a selective reduced viability was observed in cancer cells compared to
the normal cells. However, when using DMEM/F12-based medium no selective effect was observed.
Considering the challenges in setting up comparable experimental conditions in order to elucidate
a selective effect of CAP on cancer cells compared to their normal counterparts, further studies are
required before selectivity of treatment can be claimed. However, differences between malignant and
non-malignant cells may explain a potential selective effect. In general, cancer cells seem to be more
sensitive to oxidative stress compared to normal cells [8]. One example for the difference of cancer
cells and normal cells is the number of aquaporins in the cell membrane—aquaporins are usually
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more abundant in cancer cells (Figure 1 1O) [18]. Originally, aquaporins have been identified as water
channels [19]. Meanwhile, it could be shown that they also facilitate the transport of free oxygen and
nitrogen species, such as hydrogen peroxide as well as other small molecules including carbon dioxide,
nitrogen monoxide, ammoniac, urea, and glycerol [20,21]. In the membrane of cells, aquaporins form
tetramers with a central pore which functions as a selective filter [8,22]. The diameter of the pore
varies among different aquaporins and determines what can pass through the pore. The diameter
of aquaporin 1 (AQ1) for example is 2.8 Å and too small to efficiently transport hydrogen peroxide
into the cell [21]. The diameter of aquaporin 8 with 3.2 Å instead is significantly larger and hence,
sufficient to transport hydrogen peroxide. Although the diameter of aquaporin 1 is relatively small
hydrogen peroxide still penetrates faster through this channel than through the lipid double layer of
the membrane [23]. So far, aquaporins 1, 3, and 8 are known to be involved in the transport of hydrogen
peroxide in mammalian cells [24]. Several experiments have shown increasing oxidative stress due to
rising intracellular ROS concentrations caused by increased expression of aquaporins [21,25]. In one
study, for example, glioma cells and non-malignant astrocytes were treated with CAP-treated medium
(DMEM) [8]. By monitoring the intracellular hydrogen peroxide content over the course of three hours
it was shown that the tumor cells accumulated hydrogen peroxide significantly faster compared to the
non-malignant astrocytes. Hence, the increased expression of aquaporins in cancer cells compared
to their non-malignant counterparts may contribute to an increased sensitivity of these cells to CAP
treatment [23].
Besides the expression of aquaporins, the diffusion of free radicals is directly dependent on the
amount of cholesterol in the membrane (Figure 1 2O). Cholesterol is the most abundant lipid in the
membrane of animal cells. It accounts for about 50% of all lipids and is of great importance providing
membrane stability and fluidity [26,27]. Lipid peroxidation by free radicals (an electron from a lipid
gets transferred to a free radical) can result in the generation of pores in the membrane with a size of
about 15 Å. These pores are large enough to allow the diffusion of different free reactive species into
the cell. A high cholesterol content in healthy eukaryotic cells results in a condensation of membrane
lipids and hence provides a barrier against the entry of reactive species such as hydrogen peroxide [28].
In tumor cells, the amount of cholesterol is often reduced compared to healthy cells making them
more vulnerable to oxidative stress [8,29,30]. If the intracellular oxidative stress triggered by free
radicals exceeds the amount that can be handled by the anti-oxidative defense system apoptosis will
be induced through a signaling cascade [31]. By means of computer simulations, the permeation
of ROS and RNS across native and oxidized phospholipid bilayers has been investigated and these
analyses revealed that the assessed RNS (i.e., NO, NO2, N2O4) and O3 can permeate more easily
through both native and oxidized phospholipid bilayers compared to hydrophilic ROS (i.e., OH, HO2,
H2O2), indicating their potential importance in plasma medicine [32]. Nitric oxide (NO) regulates
posttranslational modifications, S-nitrosation, as well as genome-wide epigenetic modifications that
can have both tumor-promoting and tumor-suppressing effects [33]. These effects have been described
to be concentration-dependent with low NO concentrations being associated with chemo-resistance,
anti-apoptosis, proliferation, metastasis, reduced immune response and angiogenesis while high
NO is associated with apoptosis, anti-proliferation, anti-angiogenesis, anti-metastasis, and immune
response [34,35]. Interestingly, in blood of breast cancer patients, high levels of NO have been
detected and increased nitric oxide synthase (NOS) activity in invasive breast tumors compared
to benign or normal breast tissue, suggesting a positive correlation between NO biosynthesis and
degree of malignancy [36,37]. Considering these already high levels of NO in cancer cells additional
CAP generated RNS may overwhelm the system and switch the NO effect from tumor-promoting
to tumor-suppressing.
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Figure 1. Overview of the current understanding of molecular mechanisms involved in the efficacy of
cold atmospheric pressure plasma (CAP) in cancer treatment 1O Aquaporins (AQ), often increased in
cancer cells, facilitate transition of reactive oxygen and nitrogen species (RONS) into the cell, while
minimal amounts may also diffuse through the cell membrane. 2O Lipid peroxidation by free radicals
leads to pore formation in the membrane and hence facilitates diffusion of reactive species into the cell.
This effect may be enhanced in cancer cells due to reduced levels of cholesterol-a lipid important for
providing membrane stability and fluidity. 3O Increased intracellular RONS interfere with calcium
signaling (e.g., through interaction with inositol trisphosphate receptor [IP3-RR] and ryanoid receptor
[RR]) resulting in increased calcium influx into cytosol. 4O Furthermore, RONS induced endoplasmic
reticulum (ER) stress leads to a calcium influx into mitochondria reducing the membrane potential and
hence inducing mitochondria-dependent apoptosis. 5O CAP induced DNA double strand breaks (DSB)
cause a DNA damage response including activation of ATM, H2AX, p53, and p73. These DSB may not
be a direct effect of CAP on DNA but rather a consequence of CAP induced apoptosis. 6O Increased
levels of RONS produced by CAP overwhelm the antioxidant system and hence limit its protective
effect against oxidative stress. 7O Reduced expression of integins after CAP treatment may explain
the reduction of adhesion, migration, and invasion after CAP treatment. 8O As a consequence of CAP
treatment necrosis, apoptosis, and senescence have been reported. Which of these processes is induced
seems to be dose-dependent. However, the underlying mechanisms that decide which process of
growth arrest or cell death as a consequence of CAP treatment is triggered still need to be further
elucidated. MAM = mitochondria-associated ER membranes.
Regarding the role of the anti-oxidative defense system including NAD(P)H, glutathione,
superoxide dismutases, catalases, and peroxidases in preventing the induction of apoptosis this system
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provides yet another mechanism that may be different between tumor cells and their non-malignant
counterparts and, hence, may result in a selective response to CAP treatment [38].
Even though final experimental evidence for the selectivity of CAP towards cancer cells is still
lacking several common differences between tumor cells and their healthy counterparts, as outlined
above, may explain an increased vulnerability of tumor cells to CAP treatment.
3. Pathways Triggered by CAP
With regard to the selectivity of CAP towards malignant cells we have discussed the influence
of aquaporins, cholesterol, and the anti-oxidative system on the efficacy of CAP. But what are the
precise mechanisms that ultimately lead to CAP-induced cell death? As described above, CAP is
not only composed of RONS but also contains further charged particles as well as UV radiation and
electromagnetic fields. All these components could play a role and have a synergistic effect. However,
studies could show that indirect treatment using CAP-treated medium exerts very similar effects
compared to direct CAP treatment [8,39]. Based on such studies it is the current understanding that
RONS are the most important component of CAP for its efficacy in killing (tumor) cells [40]. Even
though RONS seem to be most important for the efficacy of CAP other components must not be
fully disregarded. A comparison of direct and indirect CAP treatment revealed a so far unexplained
activation of human pancreas adenocarcinoma cells which renders the cells more sensitive towards
RONS [41]. This “activation” may be due to short-lived reactive species or other unknown factors that
are not present in CAP-treated medium. However, the cytotoxicity of CAP treatment still seems to
be dependent on the CAP originated reactive species. This has been illustrated by eliminating CAP
originated RONS using scavengers such as cysteine and catalase which also eliminates the cytotoxicity
of CAP treatment [42,43]. In the following sections, we will first look at the most immediate effects of
CAP originated RONS on cells and then dive deeper into the known signaling cascades triggered by
RONS and what consequences this has for the cells.
As mentioned above, a very immediate effect of RONS on the cell membrane is lipid peroxidation
(Figure 1 2O). This leads to an increased influx of reactive species into the cytoplasm. In the cell the
reactive species can now react with different molecules and influence a variety of cellular processes.
One important second messenger involved in intra- and extracellular signaling cascades is calcium
(Ca2+) which plays an essential role in cell life and death decisions. It is well known that there is a
close interaction between calcium signaling and ROS signaling [44]. A study investigating the calcium
homeostasis in melanoma cells revealed increasing calcium concentration in the cytoplasm after CAP
treatment [45]. This increase was also observed in the absence of extracellular calcium, indicating that
the added calcium originates from intracellular sources. The main storage of intracellular calcium is the
endoplasmatic reticulum (ER) which releases calcium through IP3 receptors or ryanodine receptors [46].
Both of these receptors are sensitive to ROS as well as to calcium (Figure 1 3O). By inhibiting ryanodine
receptors the calcium influx into the cytoplasm after CAP treatment was reduced to a minimum, even
in the presence of extracellular calcium, indicating that the ER is the main source of the increasing
cytosolic calcium [45]. An increase of ROS and a rapid release of calcium from the ER into the cytosol
are common features of ER stress [46]. In that respect, it is not surprising that CAP induced ER stress
has been observed in yeast as well as in human cells [47,48]. Although the ER and mitochondria have
distinct functions, they are physically connected via so called mitochondria-associated ER membranes
(MAMs). MAMs allow the exchange of calcium, lipids and metabolites between these organelles
(Figure 1 4O) [49]. ER stress induces a calcium overload in mitochondria and consequently activates
mitochondria-dependent apoptosis via release of cytochrome c [50,51]. In line with that, mitochondrial
oxidation and membrane depolarization, as well as the induction of apoptosis, has been observed
in human lymphocytes after CAP treatment [52]. Such a depolarization of mitochondria membrane
potential and thus mitochondria-mediated apoptosis as a consequence of CAP treatment has also been
observed in human cervical cancer HeLa cells [43].
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While the role of ROS has been investigated fairly well, relatively little is known regarding the
impact of RNS. The relatively high permeation probability of RNS might contribute to the induction
of mitochondrial apoptosis by disrupting the cytochrome c function. Nitric oxide (NO) for example
binds cytochrome oxidase, the terminal enzyme of the electron transport chain in mitochondria [53].
Although the mechanisms by which NO exerts its cytostatic/cytotoxic or tissue-damaging effects are
not entirely clear, blocking the cytochrome oxidase results in increased levels of intracellular ROS
followed by the induction of mitochondrial apoptosis.
Besides the interaction between ROS and calcium signaling, an increase in ROS is also associated
with the induction of DNA lesions. Such lesion include oxidative damage, DNA single strand and
DNA double strand breaks (DSB) [54–56], as well as DNA crosslinks and crosslinks between DNA
and proteins [57]. Furthermore, free radicals can cause modifications of purine and pyrimidine rings,
strand cleavage and chromosomal abnormalities [58–60]. DNA damage as a consequence of CAP
treatment has been shown in several studies. However, in these studies primarily DSB have been
assessed by detection of γH2AX, a phosphorylated form of the histone H2AX. Phosphorylation of
H2AX serves as a well-established indirect marker for DSB (Figure 1 5O). The induction of DSB by
CAP is dependent on the distance of the CAP source to the cells as well as on the treatment time [61].
While 30 s treatment led to DSB in 60% of oral cancer cells, treatment for 120 s induced DSB in 80%
of the cells. Similar findings have been reported for glioblastoma cells which showed increased DSB
after 180 s treatment [62]. Interestingly, this increase in DSB was first detected 72 h post-treatment.
A multiphase cell cycle arrest associated with DSB and a subsequent apoptosis induction was also
observed in glioblastoma and colorectal carcinoma cells [42]. Here the DSB have been detected three
hours after CAP treatment. Likewise, DSB have been observed three hours after treatment in mouse
melanoma cells [63]. Since H2AX is phosphorylated by the ataxia telangiectasia mutated (ATM) kinase
it is not surprising that an increased expression of this kinase has been observed after CAP treatment in
oral cavity squamous cell carcinoma cells [64]. Also, activation of other substrates of ATM involved in
signaling apoptosis such as p53 and p73 has been observed in oral cavity squamous cell carcinoma and
melanoma cells [64–66]. While it has been shown that apoptosis can be induced by ROS through calcium
signaling and alteration of the mitochondrial membrane potential (described above) the importance
of ATM for apoptosis induction in response to DNA damage has been shown by small interfering
(siRNA) knockout experiments. Knockout of ATM resulted in a significant reduction of apoptosis in
squamous cell carcinoma cells [64]. Despite these findings, DSB may not be a direct effect of CAP
mediated low-ROS on DNA but rather a consequence of CAP induced apoptosis. Blocking apoptosis
and p38 MAPK signaling abolished increased γH2AX after CAP treatment in human lymphocytes
while UV induced γH2AX was independent of apoptosis [67]. Cell death and growth arrest caused by
CAP treatment will be discussed in more detail further down.
Reactive species are not only produced by external sources such as CAP but are also normal
by-products of cellular metabolism. In order to counteract oxidative stress and hence prevent the
formation of DNA lesions and the induction of apoptosis, cells have evolved a defense system against
oxidation (Figure 1 6O) [68]. An important role in this intracellular antioxidant system play thiols by
protecting against oxidative and free radical damage [69]. The most abundant intracellular thiol is
glutathione (GSH) [70,71]. The amount of GSH increased after CAP treatment in T lymphocytes and the
GSH was also significantly oxidized by the treatment [52]. Similarly, plasma treatment decreased the
ratio of glutathione to glutathione disulfide (GSH/GSSG) and NADPH/NADP+ in cancer cells [72,73].
The oxidation from GSH to GSSG is catalyzed by glutathione peroxidases. N-acetyl-cysteine (NAC), a
precursor of intracellular GSH is widely used as a scavenger and has been shown to effectively inhibit
the increase of intracellular ROS in CAP-treated cancer cells [43,74]. Furthermore, the addition of
pyruvate to the culture medium significantly suppressed ROS levels in a lung adenocarcinoma cell
line [39]. Besides glutathione peroxidase the intracellular antioxidant system also includes further
enzymes such as catalase (catalyzes the decomposition of hydrogen peroxide to water and oxygen)
and superoxide dismutase (catalyzes the dismutation of the superoxide) [75,76]. The activity of these
Cancers 2020, 12, 269 7 of 19
enzymes was significantly reduced in HepG2 cells after CAP treatment [72]. Interestingly, the activity
of superoxide dismutase was reduced after high dose plasma, but slightly increased after low dose
plasma. Modulating ROS levels or targeting antioxidants for cancer treatment is not a new concept.
Significantly increasing ROS levels for example is also the basis for the anti-tumorigenic effect of
chemotherapeutics such as cisplatin, carboplatin, and doxorubicin [77,78]. To maintain high ROS
levels that allow pro-tumorigenic signaling pathways to be activated without inducing cell death many
cancer cells are dependent on an increased antioxidant system [79]. Taken together, the cell possesses a
comprehensive antioxidant system to protect against oxidative stress but if this system is overwhelmed
by CAP generated reactive species the capacity of the different players in the system is limited and
consequently cell death is induced.
Another consequence observed after CAP treatment is reduced adhesion, migration, and invasion
(Figure 1 7O). Integrins are adhesion molecules on the surface of cells and play an important role in
these processes. A significant detachment from the cell culture vessel as well as inhibited expression
of integrin α2, integrin α4 and the focal adhesion kinase (FAK) has been observed in melanoma cells
after CAP treatment [80]. Likewise, reduced migration and cell detachment in conjunction with
reduced expression of integrin β1 and integrin αv have been observed in primary fibroblasts and mouse
epithelial skin cancer cells (PAM) following CAP treatment [81]. Although these studies revealed
an association of CAP treatment with reduced expression of several integrins, the exact mechanisms
leading to the inhibition of integrins still remain to be elucidated. Nonetheless, the inhibition of
integrins may be relevant for the efficacy of CAP in cancer treatment since integrins are known to play a
crucial role in malignant transformation, inhibition of apoptosis, and the ability to metastasize [82,83].
4. Induction of Cell Death by CAP
As described above, CAP can affect several intracellular signal transduction pathways which in
turn determine the fate of the cell and may trigger cell death. As a consequence of CAP treatment
necrosis or apoptosis may be induced but also the induction of senescence as well as autophagy
have been observed (Figure 1 8O). Which of these processes is induced seems to be dose-dependent.
While senescence, a well-known irreversible growth arrest in response to stress such as oxidative
stress and DNA damage [84], may be induced by relatively short treatments with CAP, apoptosis,
and necrosis are induced by prolonged treatment times. For example, melanoma cells treated with
higher doses (≥15 s at 1.4 W/cm2) using a Floating Electrode Dielectric Barrier Discharge (FE-DBD)
plasma source died through necrosis, while very low doses (5 s at 0.8 W/cm2) induced apoptosis in
these cells [85]. Interestingly, even the higher doses used in these experiments were still below the
threshold of damaging healthy tissue [86]. Also using a plasma jet, a treatment time and gas mixture
dependent induction of necrosis or apoptosis has been observed in V79-4 cells (normal fibroblasts
isolated lung tissue of a Chinese hamster) [87]. Highlighting a difference between primary cells and cell
lines, Hirst and colleagues observed necrosis and autophagy in primary prostate epithelial cells and
apoptosis and necrosis in cell lines [88]. A predominantly non-accidental form of necrosis due to the
interaction of CAP with the extracellular environment was observed by treatment of normal primary
fibroblasts using a Helium Guided Ionization Waves (He-GIW) device [89]. Another study showed
DNA fragmentation followed by the induction of apoptosis after treatment of head and neck squamous
cell carcinoma cells using the Surface Micro Discharge (SMD) plasma technology [90]. Besides necrosis,
apoptosis and autophagy also senescence has been observed after CAP treatment [65]. This induction
of senescence by SMD generated CAP in melanoma cells is dose-dependent and depends on cytosolic
influx of calcium [45]. While sub-lethal doses of CAP in this setting induced senescence, higher doses
resulted in the induction of apoptosis [65]. Taken together, different modes of growth arrest and cell
death have been observed as a consequence of CAP treatment. While various studies show a clear
dose dependency, other factors such as cell type and plasma source may also influence the outcome.
Further studies are required to decipher the exact molecular mechanisms and decision points that
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determine which of these processes will be induced in response to a disturbed redox balance caused by
CAP treatment.
5. CAP Interaction with the Tumor Microenvironment
In order to understand the effect of plasma, not only the interactions between plasma and the tumor
cell itself are important, but also the relationship to the tumor microenvironment (TME). The tumor
microenvironment plays an important role in cell survival, growth, invasion- and metastasis of the
tumor cells. Furthermore, the TME plays a crucial role for the efficacy of various chemotherapies [91].
Effects of CAP have been observed on different parts of the TME, which is composed of malignant
cells, immune cells, endothelial cells, fibroblasts, tumor vasculature and the extracellular matrix,
which are in constant communication with each other. In addition to the various cell types, the
TME consists of collagen, elastin, fibronectin, glycoproteins, and proteoglycan [92]. It has been
observed that prolonged treatment with CAP inhibits cell viability and collagen production of murine
fibroblasts [93]. A reduction in collagen secretion and the migration behavior was also observed after
CAP treatment in keloid fibroblasts, which, like tumor-associated fibroblasts, show an overproduction
of collagen [94,95]. Moreover, in vitro studies have shown that CAP is able to destroy collagen [96].
Eisenhauer and colleagues showed that high doses of CAP prevent extracellular matrix interactions
with cells and bone formation [97]. The desmoplastic reaction that has already been shown in the
clinical use of CAP for the treatment of head and neck cancer also suggests an increased deposition of
collagen [98,99]. Other components of the extracellular matrix, such as hyaluronic acid or fibronectin,
can also be damaged or influenced by ROS, although the relationship to CAP has not been sufficiently
investigated [100,101]. Particular attention is paid to the effect of plasma on the communication between
cells but also between cells and the extracellular matrix and the influence on this communication by
treatment with plasma. Some cells sustain damage from plasma treatment even though they are not
treated directly. This may be explained by communication between the cells. The bystander effect
enables cells to send signals to untreated neighboring cells. Therefore, soluble molecules such as
chemokines or growth factors and different junctions can be used. The oxidative stress caused by
plasma treatment, influences or damages these signaling molecules [102–104]. Alternatively, apoptosis
may occur in neighboring cells due to the formation of secondary oxygen and the inactivation of the
membrane-bound catalase [105,106]. It has also been shown that calcium ions can be transported from
apoptotic to non-apoptotic neighbour cells via gap junctions, which also explains the widespread effect
of plasma [107]. A comprehensive review on CAP effects regarding numerous other parts of the TME
was provided by Privat-Maldonado et al. [92].
6. Induction of an Immune Response through CAP Treatment
The Nobel Prize for Medicine or Physiology 2018 for checkpoint cancer immunotherapies has
highlighted the importance of the immune system as a critical contributor to target tumor cells [108].
Because plasma treatment is a local therapy possibly modulating the tumor microenvironment, several
reports have addressed the possibility of plasma to stimulate immunity to possibly support anticancer
treatment [109,110]. Two lines of research are currently pursued to disentangle the effect of plasma
treatment in anticancer immunity. One is the ability of plasma to affect immune cells directly, which
leads to their activation or selection of specific subpopulations of immune cells, for example [111].
The second is an indirect activation of immune cells via plasma-mediated tumor cell death and
pro-inflammatory signals in the microenvironment [109,110].
Cellular immunity is comprised of innate and adaptive immune cells. While the former recognize
evolutionarily conserved epitopes on target structures, the latter can diversify their receptor repertoire
to respond to new or mutated antigens. Phagocytes, such as neutrophils, dendritic cells, and
macrophages are some of the primary cell types shaping innate immune responses [112]. Macrophages
are present in virtually all types of tissues and essential in shaping the local balance of inflammation
and anti-inflammation [113]. Plasma-treated cell line-derived macrophages were shown to have
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a higher migratory activity [114], cytokine release [115], and augmented antitumor toxicity [116],
which contributed to elevated levels of TNFα [117] when investigated in transwell co-culture systems.
Moreover, plasma treatment was suggested to modulate the differentiation patterns of primary
murine [118] and human monocyte-derived macrophages [119]. Using human cell line-derived
macrophages, this change in differentiation was also attributed to enhanced antitumor effects in direct
co-culture experiments [102]. In Vivo, elevated levels of macrophages were found in pancreatic cancer
tissue in response to therapeutically active plasma-conditioned liquids [120]. For neutrophils, there
is increasing evidence that their increased presence in tumors and blood is associated with poor
prognosis in cancer patients [121]. To date, there is only a single report on plasma-treated neutrophils
that describes elevated neutrophil extracellular-trap (NET) formation in response to gas plasma
treatment [122]. In mild contradiction to that, evidence of increased intracellular neutrophils and NET
formation was found in pancreatic cancer subjected to plasma-conditioned liquid [123], which was
associated with survival benefit in these mice. For other innate immune cells, such as NK cells and mast
cells, there have been no reports in the context of cancer immunology. For primary NK cells, it is known
only that they are similarly sensitive to plasma-induced cell death compared to adaptive lymphocytes,
while activated NK cells are less prone to plasma-mediated apoptosis [124]. Similarly, only very few
reports have reported response of cells of the adaptive immune system with regard to activation
putatively important to anticancer immunity. While activated primary T-cells were also found less
sensitive to apoptosis following exposure to plasma [124]. Interestingly, T-cells actively counteract
plasma-mediated oxidative stress [52] while increasing markers associated with their activation such as
CD69 and HLA-DR [125]. For both innate and adaptive immune cells, plasma treatment regulated the
protein content of microparticles released from these cells [126], with microparticles being a biological
entity increasingly recognized in cancer research [127].
Extensive plasma treatment times or energies damage tumor cells. There is increasing evidence
that such oxidation-induced cell death takes place in a pro-immunogenic manner. The paradigm of
immunogenic cancer cell death (ICD) predicts that tumor antigens presented in an immunogenic but
not tolerogenic context orchestrate antitumor T-cell responses [128]. If tumor cell death comes with
enhanced levels of damage-associated molecular patterns (DAMPs, such as ATP [129]) being paralleled
by an increased uptake of tumor material via dendritic cells (DCs, via, e.g., calreticulin; CRT), the latter
present tumor antigen to antitumor T-cells together with sufficient T-cell co-stimulation in the draining
lymph node [130]. The activated T-cells proliferate and later reach the tumors and their metastases
throughout the whole body via the blood. Within the tumor microenvironment, they recognize tumor
antigens and lyse the target cells, helping the body to fight cancer using its endogenous weapons
provided by the immune system. Using direct plasma treatment or plasma-conditioned liquids,
ICD has been observed in vitro in a number of tumor cell types including, for instance, pancreatic
cancer, colorectal cancer, lung cancer, and malignant melanoma [99,131–140]. Due to the extensive
poly-pragmasia of plasma sources used in the field of plasma medicine, the central mechanisms
underlying plasma-induced ICD have not been commonly unraveled. One of the sources initiating
ICD is a dielectric barrier discharge used by Lin et al. The authors elegantly demonstrated a strong
dependence of ICD on short-lived reactive species with an only minor contribution of other plasma
effectors [131]. However, the exact types of the main species being critical for plasma-induced ICD that
would allow optimization of an anti-cancer plasma source specifically targeting ICD pathways were not
identified. Moreover, the plasma source is not accredited as medical device, hampering translational
efforts of this innovative therapy. For the accredited plasma medical device kINPen, clinical evidence
has been reported in the therapy of stage IV head and neck cancer patients [99,141–143]. A role of
any enhanced immune-mediated effects in this treatment is suggested but not clearly demonstrated
yet [98]. However, preclinical animal models suggest involvement of anticancer immunity. An increase
of intratumoral T-cells was observed in plasma-treated melanoma [144] and pancreatic cancer exposed
to plasma-condition liquid [123]. In the latter, an increase of CRT expression was observed in tumors,
which was also found in a model colorectal cancer subcutaneously injected into the skin of mice [135].
Cancers 2020, 12, 269 10 of 19
In this model, the authors also reported an increase of intratumoral CD11c+ expression, indicative
of DCs. In addition, van Loenhout and colleagues recently reported increased activation of DCs
co-cultured with tumor cells exposed to plasma-conditioned liquid [134]. All these data suggest that
plasma treatment of tumor cells shapes antitumor immunity, although the extent of such an effect is
subject to further research.
7. Clinical Application of CAP
While in vitro studies using cell cultures and in vivo studies using mouse models indicate a huge
potential of CAP for cancer treatment, the efficacy ultimately has to be proven for human patients in a
clinical setting. First experiences have been reported from treating locally advanced head and neck
cancers in six patients [98,99]. Using a plasma jet (kINPen MED) these patients have been treated
within one week in three cycles of single applications. This treatment resulted in improved quality of
life through a reduction odor and pain medication demands. Two patients showed a partial remission
for at least nine month and biopsies from tissues in remission revealed a moderate amount of apoptotic
tumor cells. Similar results have been reported in a second study including 12 patients [99]. Analyses
of resected CAP-treated tumor tissue revealed an increase of apoptotic cells compared to non-treated
tissue [143]. Another case series elucidated the effect of CAP on actinic keratosis (precursor lesions of
squamous cell carcinomas) [145]. In this study, a total of 17 lesions have been treated. Nine lesions
showed total remission, three a partial remission and only five lesions showed only minimal or no
improvement one month after CAP treatment. Of note, no negative effects have been reported. No
inflammation, pain, or other adverse events have been observed neither during treatment, immediately
after treatment nor in the later course of the disease. Even though more patients need to be treated
more than 70% of these patients responded to the therapy [145]. In a second study including seven
patients with actinic keratosis, all patients showed a good response with a significant remission of the
actinic keratosis after seven treatments for 120 s using a plasma jet [146]. A pilot study including eight
patients with malignant pleural mesothelioma investigated the use of cold plasma for cold plasma
coagulation (CPC) [147]. CPC was performed as part of a multimodal therapy and the results indicate
CPC to be a safe technique when used on the pleura, pericardium, and diaphragm. Histological
examinations of pleural specimens revealed no detectable vital tumor cells in deeper layers of the
pleural and subpleural space. No relapse of the disease was observed during the time of the study
(median observations time was one year). These first clinical reports are very promising (summarized
in Table 1), but, of course, can only be the beginning of further clinical trials.
Table 1. Clinical studies reporting the use of CAP for treatment of (pre-) cancerous tissues.
Reference Number ofPatients Tumor Entity Plasma Source
Main Observations after CAP
Treatment
Metelmann et al.
2018 6
Locally advanced
head and neck
cancers
kINPen MED
Improved quality of life due to
reduced odor and pain
Partial remission in 2 patients
Metelmann et al.
2015 12
Advanced
squamous cell
carcinoma of the
head and neck
kINPen MED
Decreased request for pain
medication
Reduction of typical fetid odor
Reduction of microbial load
Superficial partial remission of
tumor in 4 patients
Wound healing of infected
ulcerations tumor in some cases
Schuster et al. 2016 Group I: 12Group II: 9
Advanced
squamous cell
carcinoma of the
head and neck
kINPen MED
Increase of apoptotic cells in
CAP-treated tissue compared to
non-treated tissue
Cancers 2020, 12, 269 11 of 19
Table 1. Cont.
Reference Number ofPatients Tumor Entity Plasma Source
Main Observations after CAP
Treatment
Friedman et al.
2017 5 (17 lesions) Actinic keratosis
Custom-made
device with
hand-held
electrode
(FPG10-01NM10)
Total remission of 9 lesions, partial
remission of 3 lesions, minimal or
no improvement of 5 lesions
Wirtz et al. 2018 7 Actinic keratosis Adtec Steri-Plas Number of lesions decrease in 6 of8 treated areas
Hoffmann et al.
2010 8
Pleural
mesothelioma
CPC 1500 System
(jet)
No detectable vital tumor cells in
the tissue after treatment
8. Conclusions
Reactive oxygen and nitrogen species (RONS) have been identified as the main contributors for
the efficacy of CAP in killing cancer cells. Although many studies indicate a selective effect of CAP
towards malignant cells compared to their healthy counterparts the experimental settings in many of
these studies may have influenced this finding. Nevertheless, several factors have been identified that
often differ between healthy and malignant cells and hence, may contribute to an increased sensitivity
of cancer cells to CAP. These factors such as expression of aquaporins or cholesterol or the ability to
protect against oxidative stress by the anti-oxidative system determine how many RONS can enter
the cell and interfere with intracellular signaling pathways. As a consequence of the CAP treatment
reduced adhesion, migration and invasion may contribute to a successful cancer treatment by reducing
the ability of the cells to spread and form metastasis. Furthermore, necrosis, apoptosis, senescence,
and autophagy may result from CAP treatment in a dose-dependent manner and hence, stop tumor
growth and trigger an immune response. The underlying mechanisms that decide which process of
growth arrest or cell death as a consequence of CAP treatment is triggered still need to be further
elucidated. Moreover, the different plasma sources and treatment conditions as well as cell types
and tumor entities investigated contribute to the efficacy and always need to be considered when
drawing any conclusions. In the end, great progress has been made to the understanding of underlying
mechanisms regarding the efficacy of CAP in cancer treatment, but much still needs to be done with
respect to different treatment conditions and comparison of malignant and non-malignant cells of the
same cell type and same donor. First clinical case reports support the benefits of CAP as a potential
innovative therapy for the treatment of cancers and should motivate further clinical trials to prove the
relevance of CAP in the clinic.
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